

Non-genetic, Exposure-related Mitochondrial Disease *(“Mitochondrial Toxicity”)*

Kendall B. Wallace, Ph.D., DABT, ATS
Professor & Associate Dean
University of Minnesota Medical School
Duluth campus

Mitochondrial Disease

- Multi-organ clinical presentation
- Metabolic phenotype
- Progressive
- Etiology
 - Genetic
 - Somatogenic/acquired (toxicity)


Mitochondrial Disease

- Etiology


1. Genetic

*mutations to
nuclear (nDNA)
&/or mitochondrial
DNA (mtDNA)*

Heritable –
X-chromosome



Mitochondrial Electron Transport Chain



	Complex I	Complex II	Complex III	Complex IV	Complex V
nDNA	35	4	10	10	12
mtDNA	7	0	1	3	2

Genetic Mitochondria Disease Foundations

Mitochondrial Disease

- Etiology
 - 2. *Somatogenic/acquired*
“Mitochondrial Toxicity”



- Pharmaceutical
- Environmental
- Occupational



Mito Action Broadcasts

(drug-induced mitochondrial disease)

- May 1, 2009
Dr. James Dykens, Pfizer Pharmaceuticals
“Drug Toxicity and Pharmaceuticals”
- June 4, 2010
Dr. Katherine Sims from Massachusetts General Hospital
“Mitochondrial Toxicity”


Multiple Targets for Drug-induced Mitochondrial Toxicity

(*Wallace, K.B. Curr Med Chem. 2015 May 13*)

Chemical Targeting to Mitochondria


Drugs & chemicals are not distributed equally throughout the cell

- Cardiolipin




- Electrical membrane potential

Mitochondrial Electron Transport Chain




Modified from: Peter S. Rabinwitch after Mandavilli et al., Mutation Research 509 (2002) 127–151




Transmembrane potentials:
~ 1 pH unit alkaline matrix
~ 180 mV negative matrix

Positively charged chemicals are drawn from the cell contents into and accumulate in mitochondria



Acids & bases

Pharmaceutical Inhibitors of Mitochondrial Electron Transport



I

Amytal
Haloperidol
Chlorpromazine
Fluphenazine
Risperidone
Clozapine
Nefazodone
Clofibrate, Fenofibrate, Ciprofibrate
Troglitazone, Rosiglitazone, Pioglitazone
Metformin, Phenformin, Buformin, Metformin
Bupivacaine, Lidocaine, Halothane, Flutamide, Dantrolene
Phenytoin

II

Cyclophosphamide
Ketoconazole
Hydrazine
Isoniazid

III

Acetaminophen
Isoflurane
Sevoflurane
Propofol

IV

Cephaloridine
Cefazolin
Cefalotin
Tamoxifen


V

Oligomycin
Propofol

Pharmaceutical Uncouplers of Mitochondrial Respiration:

Amphetamines, doxorubicin, Flufenamic acid, Diflunisal, Tolfenamic acid, Mefenamic acid, Diclofenac, Indomethacin, Naproxen, Nimuesulide


Chemical Inhibitors of Mitochondrial Electron Transport




Chemical Uncouplers of Mitochondrial Respiration


- Pentachlorophenol
- Heavy metals: Pb²⁺, As²⁺, Cd²⁺, Hg²⁺
- Paraquat
- perfluorosulfonamide


The Bigger Picture of “Mitochondrial Toxicity”




- *Substrate delivery*
- *Molecular organization*







Chemical-induced Mitochondrionopathies




Summary update

Molecular Targets for Mitochondrial Toxicity



From the mitochondrial or nuclear genome to protein incorporated into the mitochondrial structure

- Gene translation
- Protein synthesis
- Protein translocation and assembly

Chemical-induced Mitochondrionopathies



GENETIC MECHANISMS



nDNA mutations
Cytosolic ribosomes
Precursor processing


Cytosol

OM

IMS

IM

Matrix



Regulation of TOM biogenesis and function by cytosolic kinases (casein kinase 2, protein kinase A)

IMS protein
Inner membrane protein

IMP

Coupling of TIM23 complex to respiratory chain (bc_1 -COX-supercomplex) via Tim21 and Pam16/18

17 Tim23
PAM
16 Pam18
17 Pam17

Tim44 mtHsp70 Mge1

$\Delta\psi$

Small TIM chaperones

Link to protein assembly and quality control: Tim54 promotes i-AAA protease assembly

Tim54
Tim22
Tim22
TIM22 complex

Carrier protein

Protein stabilization by removal of N-terminal amino acid residues

Matrix protein

Single aa

Octapeptide


Matrix protein

(a) Presequence pathway


Depolarize membrane potential
Protease inhibitors

(b) Carrier pathway

Chemical-induced Mitochondrionopathies



mtDNA replication and translation



HOW NRTIs WORK


1. HIV REVERSE TRANSCRIPTASE

The HIV reverse transcriptase enzyme uses the HIV RNA chain as a template to synthesize a DNA copy using nucleotides in the host T-cell.

2. NRTIs


NRTIs are small molecule drugs that are very similar to the host cell nucleotides, and reverse transcriptase incorporates them into the new HIV DNA chain as if they were the endogenous nucleotides.

Natural state nucleotide



NRTI


OH group is missing in the NRTI, so the next nucleotide can't be inserted




3. DNA CHAIN TERMINATION

The difference between NRTIs and the endogenous nucleotides is that the NRTIs do not possess the chemical group necessary to allow for continued synthesis of the DNA chain. Consequently, once the NRTI is inserted into the DNA chain it is impossible for the reverse transcriptase to add any further nucleotides, resulting in termination of the DNA chain and interruption of the HIV replication process.

Examples of NRTIs



Mitochondrial Protein Synthesis Inhibitors



Antibiotics

Chloramphenicol


Tetracycline

Linezolid

At the ribosome, the RNA's message
is translated into a specific protein.

<http://www.hvatinn.is/frodleiksmolar/hvad-er-rna/>

Chemical-induced Mitochondrionopathies



Other “uncharacterized” Environmental Mitochondrial Toxicities

- Cigarette smoke
- Air pollution, particulates
- Poly aromatic hydrocarbons (PAHs)
- Herbicides 2,4-dichlorophenoxyacetic acid (2,4-D), dinoseb
- mtDNA genotoxins, mutagens
- etc.



Reports of demonstrated mitochondrial toxicity represent a “hazard” that may or may not be a “real” risk under normal or intended exposure conditions.



“hazard” versus
“risk”



Extended Readings

- Dykens, J.A. and Will, Y. (2007) The significance of mitochondrial toxicity testing in drug development. *Drug Discovery Today*, **12**, 777-785.
- Wallace, K.B. Mitochondrial Off-Targets of Drug Therapy. 2008. *Trends in Pharmacological Sciences*. **29**, 361-366.
- Cohen BH. (2010) Pharmacologic effects on mitochondrial function. *Dev. Disabil Res Rev*. **16**, 189-199.
- Begrache, K., Massart, J., Robin, M.-A., Borgne-Sanchez, A., and Fromenty, B. (2011). Drug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liver. *J. Hepatology* **54**, 773-794.
- Meyer JN, Leung MC, Rooney JP, Sendoel A, Hengartner MO, Kisby GE, Bess AS. (2013). Mitochondria as a target of environmental toxicants. *Toxicol Sci*. **134**, 1-17
- Wallace, K.B. (2014). Drug-induced mitochondrial neuropathy in children: A conceptual framework for critical windows of development. *J. Child Neurology* **29**, 1241-1248.
- Wallace, K.B. (2015). Multiple targets for drug-induced mitochondrial toxicity. (*Current Medicinal Chemistry*, **22**, *in press*).

Mitochondrial Disease v. Mitochondrial Toxicity

Genetic v. Environmental



Thank you

